Head-to-head evidence
Oleclumab vs PT199
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: CD73 · full Non-Small Cell Lung Cancer pipeline
Oleclumab
Developed by MedImmune LLC
NCT03822351 · Phase 2 · completed
Participants were randomized among three treatment groups, including durvalumab monotherapy as the comparator, but the study was open-label rather than blinded; 60 participants received durvalumab plus oleclumab and 67 received durvalumab alone. The clinical primary endpoint, RECIST 1.1 objective response rate, was numerically higher with oleclumab, but statistical significance of the comparison was not reported, so the result remains unclear.
Next expected readout: April 2028 · NCT07146230 (registry estimate)
PT199
Developed by Phanes Therapeutics
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2027 · NCT05431270 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Oleclumab's landscape · PT199's landscape